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OBJECTIVE
Recent studies have suggested that nonalcoholic fatty liver disease (NAFLD) is
associated with an increased risk of heart rate–corrected QT interval prolongation
and atrial ﬁbrillation in patients with type 2 diabetes. Currently, no data exist
regarding the relationship between NAFLD and ventricular arrhythmias in this
patient population.
RESEARCH DESIGN AND METHODS
We retrospectively analyzed the data of 330 outpatients with type 2 diabetes
without preexisting atrial ﬁbrillation, end-stage renal disease, or known liver
diseases who had undergone 24-h Holter monitoring for clinical reasons between
2013 and 2015. Ventricular arrhythmias were deﬁned as the presence of non-
sustained ventricular tachycardia (VT), >30 premature ventricular complexes
(PVCs) per hour, or both. NAFLD was diagnosed by ultrasonography.
RESULTS
Compared with patients without NAFLD, those with NAFLD (n = 238, 72%) had a
signiﬁcantly higher prevalence of >30 PVCs/h (19.3% vs. 6.5%, P < 0.005), non-
sustained VT (14.7% vs. 4.3%, P< 0.005), or both (27.3% vs. 9.8%, P< 0.001). NAFLD
was associated with a 3.5-fold increased risk of ventricular arrhythmias (unad-
justed odds ratio [OR] 3.47 [95% CI 1.65–7.30], P < 0.001). This association
remained signiﬁcant even after adjusting for age, sex, BMI, smoking, hyperten-
sion, ischemic heart disease, valvular heart disease, chronic kidney disease,
chronic obstructive pulmonary disease, serum g-glutamyltransferase levels, med-
ication use, and left ventricular ejection fraction (adjusted OR 3.01 [95% CI 1.26–
7.17], P = 0.013).
CONCLUSIONS
This is the ﬁrst observational study to show that NAFLD is independently associ-
ated with an increased risk of prevalent ventricular arrhythmias in patients with
type 2 diabetes.
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Nonalcoholic fatty liver disease (NAFLD)
is increasingly diagnosed worldwide and
is the most common chronic liver dis-
ease among patients with type 2 diabe-
tes (occurring in up to 75% of these
patients) (1,2). In addition, patients
with type 2 diabetes are at higher risk
for development of the most severe
forms of NAFLD, such as nonalcoholic
steatohepatitis, advanced ﬁbrosis, and
cirrhosis (3,4).
Over the past 10 years, it has become
increasingly clear that NAFLD is not only
associated with liver-related mortality
or morbidity, but also that it is a multi-
system disease that affects a variety of
extrahepatic organ systems, including
the vascular system and the heart
(5,6). To date, there is clear evidence
indicating that ischemic heart disease
(IHD) is the leading cause of mortality
in patients with NAFLD (5,6). Convincing
evidence also substantiates the exis-
tence of a link between NAFLD and sub-
clinical myocardial remodeling and
dysfunction, valvular heart diseases
(VHDs) (i.e., aortic valve sclerosis and
mitral annulus calciﬁcation), and atrial
ﬁbrillation (7).
To date, although NAFLD is associated
with a substantially increased risk of car-
diac events and death (5,6), there is a
paucity of published data regarding the
association between NAFLD and the risk
of ventricular arrhythmias, which are an
established risk factor for sudden car-
diac death. Preliminary evidence has
suggested that NAFLD is associated
with an increased prevalence of heart
rate–corrected QT interval prolongation
(i.e., an established risk factor for ventric-
ular arrhythmias), independent of many
cardiometabolic risk factors, both in pa-
tients with and without diabetes (8,9).
However, to our knowledge, no studies
have assessed the association between
NAFLD and the presence of ventricular
arrhythmias seen on 24-h Holter moni-
toring. This issue could have important
clinical implications because it might
explain the increased risk of cardiac
events and death observed among
patients with NAFLD. In particular, an in-
creased number of premature ventricu-
lar complexes (PVCs) (e.g., .30/h),
nonsustained/sustained ventricular
tachycardia (VT), or both are associated
with adverse cardiac outcomes in pa-
tients both with and without established
heart disease (10–15).
Therefore, the major aim of this study
was to examine the association between
NAFLD diagnosed on ultrasonography
and the risk of prevalent ventricular ar-
rhythmias (deﬁned as the presence of
VT, .30 PVCs/h, or both) in a sample
of patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS
Patients
For this study, we retrospectively ana-
lyzed the electronic records of all white
outpatients with established type 2 di-
abetes (according to widely accepted
diagnostic criteria) who regularly at-
tended our diabetes clinic and who
had undergone a ﬁrst 24-h Holter mon-
itoring for clinical reasons (e.g., palpita-
tions, presyncope, syncope, chest pain,
electrocardiographic abnormalities, or
the presence of multiple cardiovascular
risk factors) at our cardiology outpatient
service over the last 2 years (September
2013 through October 2015).
As detailed in Fig. 1, for the purpose
of this study we excluded patients with
type 2 diabetes with 1) preexisting
permanent/persistent atrial ﬁbrilla-
tion; 2) a pacemaker or implantable cardi-
overter deﬁbrillator; 3) missing ultrasound
data of the liver; and 4) a documented
history of cancer, end-stage renal disease,
cirrhosis of any etiology, or other known
causes of chronic liver disease, including
viral hepatitis and excessive alcohol in-
take (deﬁned as intake of .30 g/day
alcohol for men and .20 g/day for
women). On the basis of these criteria,
330 outpatients (213 men and 117
women, mean age 70 6 8 years) with
type 2 diabetes were identiﬁed and in-
cluded in the ﬁnal analysis. It is important
to note that in our diabetes clinic, an ultra-
sound examination of the liver is almost
routinely performed among the outpa-
tients with type 2 diabetes.
The local ethics committee approved
the study protocol. The ethics commit-
tee exempted our research from the in-
formed consent requirement because
we only accessed retrospectively a dei-
dentiﬁed database for the purpose of
data analysis.
Clinical and Laboratory Data
BMI was calculated by dividing weight
(in kilograms) by height (in square me-
ters). Blood pressure was measured
with a mercury sphygmomanometer at
the right upper arm using an appropri-
ate cuff size after the patient had been
seated quietly for at least 5 min. Pa-
tients were considered as having hyper-
tension if their blood pressure was
$140/90 mmHg or if they were taking
antihypertensive drugs. Information
regarding alcohol consumption and
medication use was obtained from all
patients via medical visit interviews.
Venous blood samples were drawn in
the morning after an overnight fast.
Measurements of the levels of serum
liver enzymes, lipids, creatinine (mea-
sured using a Jaffe´ rate blanked and
compensated assay), electrolytes, thyroid-
stimulating hormone, and other biochem-
ical blood attributes were obtained using
standard laboratory procedures. The nor-
mal ranges for serum aspartate amino-
transferase, alanine aminotransferases
(ALTs), and g-glutamyltransferase (GGT)
in our laboratory were 10–40 units/L for
women and 10–50 units/L for men, re-
spectively. LDL cholesterol was calculated
Figure 1—Details of the study design.
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using the Friedewald equation. Hemo-
globin A1c (A1C) was measured using an
automated high-performance liquid
chromatography analyzer (HA-8140;
Menarini Diagnostics, Florence, Italy);
the upper normal limit for our labora-
tory was 5.6%. The estimated glomeru-
lar ﬁltration rate (eGFR) was estimated
using the four-variable Modiﬁcation of
Diet in Renal Disease (MDRD) study
equation (16). Albuminuria was mea-
sured using an immunonephelometric
method on amorning spot urine sample
and expressed as the albumin-to-creat-
inine ratio. The presence of chronic kidney
disease (CKD) was deﬁned as an eGFRMDRD
,60 mL/min/1.73 m2, macroalbuminuria
(deﬁned as a urinary albumin-to-creatinine
ratio of .300 mg/g), or both; as previ-
ously reported, patients with end-stage
renal disease (deﬁned as either eGFRMDRD
,15 mL/min/1.73 m2 or dialysis) were
excluded from the study. The presence
of IHD was deﬁned as a documented his-
tory of myocardial infarction, angina, or
coronary revascularizations. VHD was de-
ﬁned as described in the medical records,
including diagnostic symptoms and echo-
cardiogram results. The presence of
chronic obstructive pulmonary disease
(COPD) was conﬁrmed by reviewing
medical records, including diagnostic
symptoms and the results of lung func-
tion tests. A preexisting history of hyper-
thyroidism (secondary to Graves disease,
toxic multinodular goiter, toxic adenoma,
or other less common etiologies) was con-
ﬁrmed by reviewing the medical records,
and included hormone results from labo-
ratory tests and thyroid imaging reports.
All patients were euthyroid at the time of
the medical examination. The presence of
atherosclerotic plaques (i.e., stenosis
$50%) at the level of either the internal
or common carotid arterieswas diagnosed
via echo-Doppler scanning. Finally, the
presence of lower-extremity sensory
neuropathy was also recorded in all par-
ticipants via clinical examination and
biothesiometer.
Twenty-Four-Hour Holter Monitoring,
Echocardiography, and Liver
Ultrasonography
The 24-h Holter monitoring, echocardi-
ography, and liver ultrasonography ﬁnd-
ings for all participants were read before
enrollment into the study. All 24-h Holter
monitoring (Seer Light-DC3V Compact Dig-
italHolter;GEHealthcare)wereperformed
at our institution. Experienced cardiolo-
gists analyzed the results of Holter moni-
toring. The number of PVCs, the mean
hourly PVC number, and the number of
sustained or nonsustained VT episodes
were recorded for all patients. VT was de-
ﬁned as three or more PVC beats with a
mean R-R interval length of,600 ms, and
was considered to be sustained if it lasted
.30 s, produced syncopeor cardiac arrest,
or required cardioversion (17). The num-
ber of atrial premature complexes (APCs),
mean hourly APC number, and the num-
ber of episodes of paroxysmal supraven-
tricular tachycardia (SVT) or paroxysmal
atrial ﬁbrillation were also recorded.
Experienced cardiologists performed a
transthoracic conventional echocardiog-
raphy (Vivid 7; GE Vingmed, Horten, Nor-
way) at our institution in a subset of
patients (n = 265, 80.3%of total). Conven-
tional echocardiography was used to
measure the left ventricular (LV) diame-
ter, wall thickness and ejection fraction
according to international standard crite-
ria (18). No signiﬁcant differences were
observed in demographic variables and
the prevalence of NAFLD or ventricular
arrhythmias between those with (n =
265) and those without (n = 65) echocar-
diographic data (data not shown).
Experienced radiologists performed
liver ultrasonography for all patients.
Hepatic steatosis was diagnosed based
on characteristic ultrasonographic fea-
tures, such as diffuse hyperechogenicity
of the liver relative to the kidneys, ultra-
sound beam attenuation, and poor visu-
alization of the intrahepatic vessel
borders and diaphragm (19). Liver ultra-
sonography has high sensitivity and
speciﬁcity for detecting moderate and
severe hepatic steatosis. However, the
sensitivity is reduced when the hepatic
fat inﬁltration identiﬁed via liver biopsy
is,30% (19). In this study, a semiquan-
titative ultrasonographic scoring of the
degree of hepatic steatosis was not
available.
Statistical Analysis
Data are presented as the mean 6 SD,
median and interquartile range, or per-
centages. Based on previous studies
(12,13,17), ventricular tachyarrhythmia
was deﬁned as the presence of non-
sustained VT, .30 PVCs/h, or both.
Differences in clinical and biochemical
characteristics as well as in 24-h ambu-
latory Holter monitoring data among
patients stratiﬁed by their NAFLD (Table
1) or ventricular arrhythmia (Supple-
mentary Table 1) statutes were assessed
using the unpaired t test (for normally
distributed variables) and the Mann-
Whitney U test (for non-normally distrib-
uted variables (i.e., diabetes duration,
levels of serum triglycerides and liver en-
zymes, as well as the number of PVCs,
APCs, and VT episodes seen over 24 h
on Holter monitoring). The x2 test was
used to test for between-group differ-
ences among the categorical variables.
A binary logistic regression analysis was
used to examine the association be-
tween NAFLD and the presence of ven-
tricular arrhythmias, which was included
as the dependent variable. The following
four forced-entrymultivariate logistic re-
gression models (Table 2) were per-
formed: an unadjusted model; a model
adjusted for age and sex (model 1); a
model adjusted for age, sex, BMI, hyper-
tension, smoking, IHD, VHD, CKD, COPD,
and serum GGT levels, and antiarrhyth-
mic drug use (model 2); and, ﬁnally, a
model adjusted for the same variables
included in model 2 plus LV ejection frac-
tion (model 3). The covariates included in
these forced-entry multivariate regression
models were chosen as potential con-
founding factors based on their signiﬁ-
cance in univariate analyses or their
biological plausibility (i.e., age, smoking,
hypertension, IHD, VHD, CKD, and antiar-
rhythmic drug use). A stepwise logistic re-
gression analysis with a forward selection
of covariates was also performed (using
the likelihood ratio method). A P value of
,0.05 was considered to be statistically
signiﬁcant.
RESULTS
Of the 330 outpatients with type 2 di-
abetes included in this study, 238
(72.1%) met the diagnostic criteria for
NAFLD (i.e., hepatic steatosis on ultraso-
nography among patients with no history
of excessive alcohol intake or other
known causes of chronic liver disease),
and 92 (27.9%) did not. Of the entire
sample, 74 patients (22.4%) had ven-
tricular arrhythmias (i.e., nonsustained
VT, .30 PVCs/h, or both), whereas
the remaining 256 patients (77.6%)
did not. No patients had sustained VT,
serum electrolyte disturbances, or
hyperthyroidism.
Table 1 shows the clinical, biochemi-
cal, and 24-h Holter monitoring data of
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patients stratiﬁed by NAFLD status.
Comparedwith patients without NAFLD,
those with NAFLD had higher values of
body weight, BMI, and serum triglycer-
ide and GGT levels. The prevalence of
COPD and the percentage of patients
using diuretic or b-blocker agents was
also higher among patients with NAFLD,
whereas the percentage of those treat-
ed with insulin was lower. In addition,
patients with NAFLD tended to have
higher systolic blood pressure and a
higher prevalence of diabetic lower-
extremity sensory neuropathy. The two
groups of patients did not signiﬁcantly
differ in terms of sex, age, diabetes du-
ration, diastolic blood pressure, A1C,
HDL cholesterol, LDL cholesterol, elec-
trolytes, eGFR, hypertension, IHD, and
other comorbidities (e.g., VHD, CKD,
prior hyperthyroidism, or carotid artery
stenoses), or in terms of the use of oral
hypoglycemic, lipid-lowering, antiplatelet/
anticoagulant, and antihypertensive
drugs (except for b-blockers) or antiar-
rhythmic agents (which were used by
only a few patients). Table 1 also shows
that patients with NAFLD had a lower LV
ejection fraction and higher 24-h PVC
values, mean hourly PVC values, 24-h
APC values, and mean hourly APC values
compared with those without NAFLD.
They also showed a higher prevalence
of both paroxysmal SVT and paroxysmal
atrial ﬁbrillation.
Notably, as shown in Fig. 2, patients
with NAFLD had a markedly higher prev-
alence of nonsustained VT,.30 PVCs/h,
or both compared with those with-
out NAFLD (P values ,0.005–0.001 for
between-group differences).
Supplementary Table 1 shows the
clinical, biochemical, and 24-h Holter
monitoring data of the patients strati-
ﬁed by ventricular arrhythmia status.
Compared with patients without ven-
tricular arrhythmias, those with ventric-
ular arrhythmias were more likely to be
male and have a lower LV ejection frac-
tion as well as higher serum GGT levels,
CKD rates, and lower-extremity sensory
neuropathy. Notably, they also showed a
higher prevalence of NAFLD. Regarding
the 24-h Holter monitoring data, patients
with ventricular arrhythmias had higher
24-h APC values, and, as expected, higher
24-h PVC values, higher mean hourly PVC
values, andmore VT episodes. None of the
other clinical and biochemical parameters
Table 1—Clinical, biochemical, and 24-h Holter monitoring data of patients with
type 2 diabetes stratiﬁed by NAFLD status
Without NAFLD
(n = 92)
With NAFLD
(n = 238) P value
Male sex/female sex (n) 58/34 155/83 0.723
Age (years) 69.5 6 8.4 70.6 6 7.9 0.250
Weight (kg) 74.0 6 13.4 83.1 6 14.9 ,0.001
BMI (kg/m2) 26.1 6 3.6 29.7 6 4.7 ,0.001
Diabetes duration (years) 7.3 (6–11) 7.3 (5–11) 0.289
Smoking 16.3 23.6 0.082
Systolic blood pressure (mmHg) 136.5 6 16.4 140.5 6 17.5 0.060
Diastolic blood pressure (mmHg) 76.3 6 8.9 77 6 9.3 0.542
Fasting glucose (mmol/L) 8.0 6 2.6 7.8 6 2.2 0.445
A1C (%) 7.3 6 1.2 7.3 6 1.3 0.884
A1C (mmol/mol) 56 6 6 56 6 7 0.884
Total cholesterol (mmol/L) 4.1 6 1.0 4.3 6 1.0 0.146
HDL cholesterol (mmol/L) 1.4 6 0.4 1.3 6 0.3 0.099
LDL cholesterol (mmol/L) 2.2 6 0.9 2.3 6 0.9 0.354
Triglycerides (mmol/L) 1.3 (0.8–1.8) 1.4 (1.1–1.9) 0.010
AST (units/L) 19 (14–23) 19 (15–24) 0.203
ALT (units/L) 20 (15–28) 23 (17–29) 0.082
GGT (units/L) 28 (19–39) 30 (20–47) 0.031
eGFRMDRD (mL/min/1.73 m
2) 71.7 6 21.0 71.5 6 23.7 0.948
Na (mmol/L) 139.7 6 2.8 139.5 6 2.5 0.987
K (mmol/L) 4.2 6 0.4 4.1 6 0.3 0.621
Hypertension 85.8 91.2 0.164
IHD 21.7 23.9 0.658
VHD 2.2 2.9 0.694
COPD 2.2 7.9 0.032
CKD 22.8 31.1 0.131
Prior hyperthyroidism 1.1 0.8 0.835
Diabetic sensory neuropathy
(n = 270) 15.5 24.9 0.079
Carotid artery stenosis $50%
(n = 325) 4.3 6.0 0.663
Oral hypoglycemia drug users 44.5 52.9 0.197
Insulin users 47.8 35.7 0.044
ACE inhibitors/ARB users 56.5 63.0 0.280
Calcium-channel blocker users 22.8 28.5 0.288
Diuretic users 38.0 50.4 0.042
b-Blocker users 22.8 39.0 0.006
Nitroderivate users 5.4 6.3 0.763
Antiarrhythmic drug users 3.2 5.4 0.386
Statin users 76.1 71.4 0.390
Antiplatelet drug users
(n = 202) 53.0 67.9 0.079
Anticoagulant drug users 7.6 7.9 0.908
LV ejection fraction (%)
(n = 265) 61.6 6 9.9 58.2 6 11.5 0.024
24-h Holter monitoring
Heart rate (bpm) 72.9 6 10.2 70.0 6 10.4 0.498
24-h PVC count (n) 16.5 (3–107) 42.5 (5–254) 0.004
Hourly PVC count (n) 1 (0–5) 2 (0–11) 0.010
Number of VT episodes (n) 0 (0–0) 0 (0–0) 0.092
24-h APC count (n) 35 (10–146) 51 (15–232) 0.046
Hourly APC count (n) 1.6 (0.3–6) 2 (1–10) 0.049
Continued on p. 1420
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ormedication use signiﬁcantly differed be-
tween the two groups of patients.
Supplementary Table 2 shows the
main clinical and biochemical charac-
teristics of the patients stratiﬁed simul-
taneously by NAFLD and ventricular
arrhythmia statutes. The four subgroups
of patients signiﬁcantly differed only in
terms of gender distribution, weight,
BMI, serum triglyceride levels, serum
GGT levels, the presence of CKD and sen-
sory neuropathy, LV ejection, and use
of b-blockers (P values for the trends).
Borderline signiﬁcant trends were also
found in serum ALT levels, COPD, use of
antiplatelet drugs, and LV ejection fraction
among the four subgroups of patients.
Conversely, no signiﬁcant differences
were found in the duration of diabetes;
A1C levels; serum electrolyte levels; smok-
ing; hypertension; IHD; VHD; and the use
of antiarrhythmic drugs and medications
for diabetes, dyslipidemia, and hyperten-
sion (except for b-blockers).
Table 2 shows the results after adjust-
ing for several potential confounding
factors regarding the association be-
tween NAFLD and the presence of ven-
tricular arrhythmias on 24-h Holter
monitoring. In univariable regression
analysis, NAFLD was associated with an
;3.5-fold increased rate of ventricular
arrhythmias (unadjusted odds ratio [OR]
3.47 [95% CI 1.65–7.30], P, 0.001). Af-
ter adjusting for age and sex (model 1),
NAFLD maintained a signiﬁcant associa-
tion with ventricular tachyarrhythmias.
The strength of this association was not
attenuated after additional adjustment
for BMI, hypertension, smoking status,
IHD, VHD, CKD, COPD, serumGGT levels,
and antiarrhythmic drug use (model 2).
Finally, additional adjustment for the LV
ejection fraction did not appreciably
weaken the association between NAFLD
and ventricular arrhythmias (model 3,
n = 265). The other independent predic-
tors of ventricular arrhythmias in model 3
were male sex, a lower LV ejection frac-
tion, and higher serum GGT levels.
Similar results were observed when
we excluded the patients who were
treated with antiarrhythmic drugs from
the analysis (n = 15, data not shown), or
when we additionally adjusted the
model 3 also for presence of diabetic
sensory neuropathy (as reported in
Table 1, these data were available
only in 270 patients); also in this latter
fully adjusted regression model (which
included 219 patients in total), NAFLD
remained signiﬁcantly associated with
ventricular arrhythmias (adjusted OR
2.46 [95% CI 1.01–6.15], P , 0.05).
We also performed a stepwise logistic
regression analysis with a forward selec-
tion of covariates (Supplementary Table
3). Also in this case, male sex (adjusted
OR 2.81 [95% CI 1.29–6.13]), higher se-
rum GGT levels (adjusted OR 1.01 [95%
CI 1.002–1.017]), lower LV ejection frac-
tion (adjusted OR 0.96 [95% CI 0.94–
0.99]), and NAFLD (adjusted OR 2.76
[95% CI 1.21–6.27]) were the only four
variables signiﬁcantly included in the ﬁ-
nal stepwise regression model.
CONCLUSIONS
This study is the ﬁrst to examine the
association between NAFLD and ventric-
ular arrhythmias, deﬁned as the pres-
ence of nonsustained VT, .30 PVCs/h,
or both in a large sample of outpatients
with type 2 diabetes referred for clini-
cally indicated 24-h ambulatory Holter
monitoring.
The major ﬁndings of our study are as
follows: 1) patients with NAFLD had a
markedly increased prevalence of non-
sustained VT,.30 PVCs/h, or both com-
pared with those without NAFLD; 2) a
complementary electrocardiographic
ﬁnding revealed that patients with
NAFLD also had a higher prevalence of
paroxysmal atrial ﬁbrillation (although
the frequency of this abnormality was
low) and a higher burden of APCs (i.e.,
higher mean hourly APC values and
more paroxysmal SVT episodes); 3)
NAFLD was associated with an approxi-
mately threefold increased risk of non-
sustained VT,.30 PVCs/h, or both even
after adjusting for a wide range of car-
diovascular risk factors and potential
confounding factors, such as age, sex,
BMI, hypertension, smoking, LV ejection
fraction, medication use, prior IHD, micro-
vascular complication status (diabetic
Table 1—Continued
Without NAFLD
(n = 92)
With NAFLD
(n = 238) P value
Paroxysmal SVT 33.6 47.4 0.023
Paroxysmal atrial ﬁbrillation 2.2 7.6 0.044
Sample size, n = 330 except where indicated. Data are expressed as the mean 6 SD, median
(interquartile range), or percentages, unless otherwise indicated. Differences between the two
groups were tested by the x2 test for categorical variables, the unpaired Student t test for
normally distributed continuous variables, and the Mann-Whitney test for non-normally
distributed continuous variables (i.e., diabetes duration, triglycerides, liver enzymes as well as
24-h PVCs, APCs, and VT episodes on Holter monitoring). ARB, angiotensin II receptor blockers;
AST, aspartate aminotransferase; K, potassium; Na, sodium.
Table 2—Independent predictors of ventricular arrhythmias in patients with
type 2 diabetes
Logistic regression models ORs 95% CIs P value
NAFLD (yes vs. no)
Unadjusted model 3.47 1.65–7.30 ,0.001
Adjusted model 1 3.39 1.60–7.20 0.001
Adjusted model 2 3.26 1.44–7.37 0.005
Adjusted model 3 3.01 1.26–7.17 0.013
Other independent predictors of ventricular
arrhythmias in model 3
Male sex 3.03 1.31–7.01 0.008
Serum GGT (units/L) 1.02 1.01–1.03 0.009
LV ejection fraction (%) 0.96 0.93–0.99 0.028
Sample size, n = 330, except for the model 3 where 265 patients were included. Data are
expressed as the OR and 95% CI, as assessed by either univariate (unadjusted) or multivariate
forced-entry logistic regression analyses. The presence of nonsustained VT,.30 PVCs/h, or both
was included as the dependent variable. Other covariates included in these forced-entry
multivariate regression models, along with NAFLD, were as follows: model 1, adjusted for age,
sex; model 2, adjusted for age, sex, BMI, hypertension (i.e., blood pressure $140/90 mmHg
and/or use of any antihypertensive agents, including b-blockers), smoking history, CKD, COPD,
IHD, VHD, antiarrhythmic drug use, or serum GGT levels; model 3, adjustment for the same
variables included in model 2 plus LV ejection fraction.
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neuropathy and nephropathy), and other
comorbidities; and 4) the other variables
that were independently associated with
an increased risk of ventricular arrhyth-
mias (besides NAFLD) were male sex, a
lower LV ejection fraction and higher se-
rum GGT levels.
Our ﬁndings might have important
clinical implications. The NAFLD-related
increases in PVCs to .30/h, nonsus-
tained VT, or both might partly explain
the increased risk of cardiac events and
mortality observed in patients with
NAFLD, and further highlights the im-
portance of assessing the global cardio-
vascular and arrhythmic risk among this
group of patients.
To date, the putative biological mech-
anisms that account for the observed
association between NAFLD and ventric-
ular arrhythmias have not been fully elu-
cidated. The most obvious explanation
for our ﬁndings is that the association
between NAFLD and ventricular ar-
rhythmias is simply an epiphenomenon
of coexisting cardiometabolic risk fac-
tors and comorbidities. However, it is
important to emphasize that the associ-
ation between NAFLD and ventricular
arrhythmias remained signiﬁcant in our
study even after adjusting for many
cardiometabolic risk factors, LV ejec-
tion fraction, preexisting IHD, and
comorbid conditions. This ﬁnding cor-
roborates previous observations report-
ing a strong association between NAFLD
and an increased risk of QTc interval
prolongation, which is a powerful risk
factor for ventricular arrhythmias (8,9).
In particular, we recently demonstrated
that NAFLD was associated with an in-
creased QTc interval among patients
with type 2 diabetes without known
liver diseases, and this association re-
mained signiﬁcant after adjusting for
age, sex, hypertension, diabetes-related
variables, LV hypertrophy, and comor-
bid conditions (8). Similarly, Hung
et al. (9) reported that the ultrasono-
graphic severity of NAFLD was associ-
ated with a higher risk for QTc interval
prolongation in a large population-
based study, independently of age,
sex, hypertension, diabetes, total cho-
lesterol, eGFR, BMI, LV hypertrophy,
history of IHD, or hypokalemia.
The results of our study suggest that
NAFLD is not simply an epiphenomenon
of ventricular arrhythmia and its coex-
isting risk factors and comorbidities
(also including IHD, lower LV ejection
fraction, and diabetic neuropathy);
rather, it might also partly contribute
to their pathogenesis. Although more
research is needed to identify mechanis-
tic clues, some putative pathophysiolog-
ical mechanisms may be proposed to
explain the strong association between
NAFLD and ventricular arrhythmias.
Growing evidence suggests that NAFLD
is not only associated with an increased
risk of cardiovascular events and death,
but is also associated with subclinical
myocardial remodeling, an increase in
LV ﬁlling pressures, and enlarged left
atrial volume (5,7,20–23). Previous
studies (24–28) have also shown that
patients with NAFLD have an increased
risk of atrial ﬁbrillation compared with
those without NAFLD. Moreover, exper-
imental evidence indicates that NAFLD
is associated with insulin resistance,
myocardial lipid toxicity, and the sys-
temic release of a myriad of proinﬂam-
matory, procoagulant, pro-oxidant, and
proﬁbrogenic mediators that play im-
portant roles in the pathogenesis of
the functional, structural, and arrhyth-
mic abnormalities of the heart (3,5–
7,29,30). NAFLD-related derangements
in myocardial function and structure
might induce alterations in ﬁber conti-
nuity and potential circuit re-entry,
which might produce electrophysiologi-
cal changes. Finally, preliminary evi-
dence also suggests that noncirrhotic
NAFLD is associated with cardiac auto-
nomic dysfunction, which is a risk factor
for ventricular arrhythmias and sudden
cardiac death (31).
Interestingly, in our study elevated
serum GGT levels were also indepen-
dently associated with an increased
risk of ventricular tachyarrhythmias. Se-
rum GGT levels have been commonly
used as a marker for excessive alcohol
consumption or liver disease. However,
because of the key role played by GGT in
the synthesis and metabolism of gluta-
thione, elevated serum GGT levels are
also a marker of increased oxidative
stress (32). Many population-based
studies have shown that moderately el-
evated GGT levels are independent,
long-term predictors of all-cause and car-
diovascularmortality (33).Recently,Alonso
et al. (25) reported that moderately ele-
vated GGT levels are also independently
associated with an increased incidence
of atrial ﬁbrillation in a community-based
study. Similarly, we found that increased
GGT levels and hepatic steatosis had ad-
ditive and independent effects on the
prevalence of permanent/persistent atrial
ﬁbrillation in a hospital-based sample of
patients with type 2 diabetes (24). Inter-
estingly, Wang et al. (34) reported that
increased GGT levels were associated
with longer QTc interval duration and
higher QT interval dispersion in patients
with newly diagnosed type 2 diabetes. In
linewith theseﬁndings, our results suggest
Figure 2—Prevalence of .30 PVCs/h, nonsustained VT, or both diagnosed on 24-h ambulatory
Holter monitoring in patients with type 2 diabetes stratiﬁed by NAFLD status.
care.diabetesjournals.org Mantovani and Associates 1421
that oxidative stress may play a role in
the development of cardiac arrhythmias
(35,36).
Although the arrhythmogenic poten-
tial of NAFLD requires further conﬁrma-
tion in future studies, we believe that
this ﬁeld of research is promising. The
pathophysiological pathways through
which NAFLD contributes to chronic in-
ﬂammation, hypercoagulation, and insulin
resistance might represent potential ther-
apeutic targets for the prevention and
treatment of myocardial remodeling and
the electrophysiological abnormalities of
the myocardium in patients with NAFLD.
The major limitations of this study are
its retrospective, cross-sectional design,
which limits our ability to establish the
temporality and causality of the ob-
served associations. Moreover, a selec-
tion bias might have occurred because
patients with missing 24-h Holter mon-
itoring data were excluded from analysis
(e.g., patients with diabetes with a more
favorable cardiovascular risk proﬁle may
be less likely to be included). Although
we believe that the patients in this co-
hort were representative of the whole
sample of outpatients with type 2 dia-
betes of similar age, who regularly at-
tended our diabetes clinic, further
investigations involving this population
are desirable. In addition, although our
statistical models were extensive, we
cannot exclude the possibility of resid-
ual confounding by some unmeasured
factors (e.g., cardiac autonomic neuro-
pathy) that might partly explain the ob-
served associations. Furthermore, the
diagnosis of NAFLD was based on ultra-
sonography and the exclusion of known
causes of chronic liver diseases; this di-
agnosis was not conﬁrmed by liver bi-
opsy, which is considered to be the
“gold standard” of NAFLD diagnosis
and its more progressive forms (e.g.,
nonalcoholic steatohepatitis). However,
we believe that it would have been haz-
ardous to perform liver biopsies in these
patients with normal or only moderately
elevated serum liver enzyme levels.
Indeed, ultrasonography enables the re-
liable and accurate detection of moder-
ate hepatic steatosis compared with
histology. A recent meta-analysis by
Hernaez et al. (19) reported that the
overall sensitivity, speciﬁcity, positive
likelihood ratio, and negative likelihood
ratio of ultrasound for the detection of
moderate-to-severe fatty liver, compared
with histology (gold standard), were 84.8%
(95% CI 79.5–88.9), 93.6% (87.2–97.0),
13.3 (6.4–27.6), and 0.16 (0.12–0.22), re-
spectively. Thus, although some nondiffer-
ential misclassiﬁcation of NAFLD based on
ultrasonography is likely, this limitation
would attenuate the magnitude of our ef-
fect measures toward null; therefore, our
data are most likely a conservative esti-
mate of the relationship between NAFLD
and ventricular arrhythmias. However,
future studies in larger cohorts of well-
characterized patients with NAFLD (as di-
agnosed either by biopsy or by magnetic
resonance-proton density fat fraction
and magnetic resonance elastography,
which are rapidly being recognized as
being as good as liver biopsies) (37,38)
are needed to better elucidate whether
the severity of NAFLD may differentially
affect the risk of ventricular arrhythmias.
Finally, because our sample was limited
to white individuals with type 2 diabetes
who were assessed at an outpatient di-
abetes clinic and referred for 24-h Holter
monitoring for clinical reasons, our re-
sults might not necessarily be generaliz-
able to other populations of individuals
with diabetes.
Despite these limitations, our study
has important strengths, including its
relatively large sample size, the com-
pleteness of the dataset, the ability to
adjust for multiple clinical risk factors
and potential confounding factors, and
the exclusion of patients with pace-
makers or implantable cardioverter de-
ﬁbrillators; and those with permanent
atrial ﬁbrillation, kidney failure, or cir-
rhosis. We believe that including pa-
tients with these complications might
have confounded our interpretations
of the data.
In conclusion, this study is the ﬁrst to
demonstrate a positive and indepen-
dent association between NAFLD and
ventricular arrhythmias among patients
with type 2 diabetes referred for clini-
cally indicated 24-h Holter monitoring.
Further larger studies are needed to cor-
roborate these ﬁndings and to better
elucidate the underlying mechanisms
responsible for this association.
Duality of Interest. No potential conﬂicts of
interest relevant to this article were reported.
Author Contributions. A.M. and G.T. con-
ceived and designed the study, analyzed the
data, and wrote the draft of the manuscript.
A.R., S.B., B.B.,M.P.,G.M., L.F., C.B., L.B., F.V., R.R.,
and I.P. researched the data and reviewed and
edited the manuscript. G.Z., E.B., and F.V. con-
tributed to discussion and reviewed and edited
the manuscript. G.T. is the guarantor of this work
and, as such, had full access to all the data in the
study and takes responsibility for the integrity of
the data and the accuracy of the data analysis.
References
1. Targher G, Byrne CD. Clinical review: nonal-
coholic fatty liver disease: a novel cardiometa-
bolic risk factor for type 2 diabetes and its
complications. J Clin Endocrinol Metab 2013;
98:483–495
2. Lonardo A, Bellentani S, Argo CK, et al.; Non-
alcoholic Fatty Liver Disease Study Group. Epi-
demiological modiﬁers of non-alcoholic fatty
liver disease: focus on high-risk groups. Dig Liver
Dis 2015;47:997–1006
3. Anstee QM, Targher G, Day CP. Progression
of NAFLD to diabetes mellitus, cardiovascular
disease or cirrhosis. Nat Rev Gastroenterol Hep-
atol 2013;10:330–344
4. Portillo-Sanchez P, Bril F, Maximos M, et al.
High prevalence of nonalcoholic fatty liver dis-
ease in patients with type 2 diabetes mellitus
and normal plasma aminotransferase levels.
J Clin Endocrinol Metab 2015;100:2231–2238
5. Byrne CD, Targher G. NAFLD: a multisystem
disease. J Hepatol 2015;62(Suppl.):S47–S64
6. Targher G, Day CP, Bonora E. Risk of cardio-
vascular disease in patients with nonalcoholic
fatty liver disease. N Engl J Med 2010;363:
1341–1350
7. Ballestri S, Lonardo A, Bonapace S, Byrne CD,
Loria P, Targher G. Risk of cardiovascular, car-
diac and arrhythmic complications in patients
with non-alcoholic fatty liver disease. World J
Gastroenterol 2014;20:1724–1745
8. Targher G, Valbusa F, Bonapace S, et al. As-
sociation of nonalcoholic fatty liver disease with
QTc interval in patients with type 2 diabetes.
Nutr Metab Cardiovasc Dis 2014;24:663–669
9. Hung CS, Tseng PH, Tu CH, et al. Nonalcoholic
fatty liver disease is associated with QT prolon-
gation in the general population. J Am Heart
Assoc 2015;4:e001820
10. Cheriyath P, He F, Peters I, et al. Relation of
atrial and/or ventricular premature complexes
on a two-minute rhythm strip to the risk of sud-
den cardiac death (the Atherosclerosis Risk in
Communities [ARIC] study). Am J Cardiol 2011;
107:151–155
11. Simpson RJ Jr, Cascio WE, Schreiner PJ,
Crow RS, Rautaharju PM, Heiss G. Prevalence
of premature ventricular contractions in a pop-
ulation of African American and white men and
women: the Atherosclerosis Risk in Communi-
ties (ARIC) study. Am Heart J 2002;143:535–540
12. Bikkina M, Larson MG, Levy D. Prognostic
implications of asymptomatic ventricular ar-
rhythmias: the Framingham Heart Study. Ann
Intern Med 1992;117:990–996
13. Bikkina M, Larson MG, Levy D. Asymptom-
atic ventricular arrhythmias andmortality risk in
subjects with left ventricular hypertrophy. J Am
Coll Cardiol 1993;22:1111–1116
14. Qureshi W, Shah AJ, Salahuddin T, Soliman
EZ. Long-term mortality risk in individuals with
atrial or ventricular premature complexes (results
from the ThirdNational Health andNutrition Exam-
ination Survey). Am J Cardiol 2014;114:59–64
1422 NAFLD and Arrhythmias in Type 2 Diabetes Diabetes Care Volume 39, August 2016
15. Lee YH, Zhong L, Roger VL, et al. Frequency,
origin, and outcome of ventricular premature
complexes in patients with or without heart dis-
eases. Am J Cardiol 2014;114:1373–1378
16. Levey AS, Bosch JP, Lewis JB, Greene T,
Rogers N, Roth D; Modiﬁcation of Diet in Renal
Disease Study Group. A more accurate method
to estimate glomerular ﬁltration rate from se-
rum creatinine: a new prediction equation. Ann
Intern Med 1999;130:461–470
17. Priori SG, Blomstro¨m-Lundqvist C, Mazzanti
A, et al.; Task Force for the Management of
Patients with Ventricular Arrhythmias and the
Prevention of Sudden Cardiac Death of the Eu-
ropean Society of Cardiology (ESC). 2015 ESC
Guidelines for the management of patients
with ventricular arrhythmias and the preven-
tion of sudden cardiac death: the Task Force
for the Management of Patients with Ventricu-
lar Arrhythmias and the Prevention of Sudden
Cardiac Death of the European Society of Cardi-
ology (ESC) Endorsed by Association for Euro-
pean Paediatric and Congenital Cardiology
(AEPC). Europace 2015;17:1601–1687
18. Lang RM, Bierig M, Devereux RB, et al.;
American Society of Echocardiography’s No-
menclature and Standards Committee; Task
Force on Chamber Quantiﬁcation; American
College of Cardiology Echocardiography Com-
mittee; American Heart Association; European
Association of Echocardiography, European So-
ciety of Cardiology. Recommendations for
chamber quantiﬁcation. Eur J Echocardiogr
2006;7:79–108
19. Hernaez R, Lazo M, Bonekamp S, et al.
Diagnostic accuracy and reliability of ultraso-
nography for the detection of fatty liver: a
meta-analysis. Hepatology 2011;54:1082–1090
20. Bonapace S, Perseghin G, Molon G, et al.
Nonalcoholic fatty liver disease is associated
with left ventricular diastolic dysfunction in pa-
tients with type 2 diabetes. Diabetes Care 2012;
35:389–395
21. Hallsworth K, Hollingsworth KG, Thoma C,
et al. Cardiac structure and function are altered
in adults with non-alcoholic fatty liver disease.
J Hepatol 2013;58:757–762
22. VanWagner LB, Wilcox JE, Colangelo LA,
et al. Association of nonalcoholic fatty liver dis-
ease with subclinical myocardial remodeling
and dysfunction: a population-based study.
Hepatology 2015;62:773–783
23. Mantovani A, Pernigo M, Bergamini C, et al.
Nonalcoholic fatty liver disease is indepen-
dently associated with early left ventricular di-
astolic dysfunction in patients with type 2
diabetes. PLoS One 2015;10:e0135329
24. Targher G,Mantovani A, Pichiri I, et al. Non-
alcoholic fatty liver disease is associated with an
increased prevalence of atrial ﬁbrillation in hos-
pitalized patients with type 2 diabetes. Clin Sci
(Lond) 2013;125:301–309
25. Alonso A, Misialek JR, Amiin MA, et al. Circu-
lating levels of liver enzymes and incidence of atrial
ﬁbrillation: theAtherosclerosis Risk inCommunities
cohort. Heart 2014;100:1511–1516
26. Targher G, Valbusa F, Bonapace S, et al.
Non-alcoholic fatty liver disease is associated
with an increased incidence of atrial ﬁbrillation
in patients with type 2 diabetes. PLoS One 2013;
8:e57183
27. Ka¨ra¨ja¨ma¨ki AJ, Pa¨tsi OP, Savolainen M,
Kesa¨niemi YA, Huikuri H, Ukkola O. Non-alcoholic
fatty liver disease as a predictor of atrial ﬁbrilla-
tion in middle-aged population (OPERA study).
PLoS One 2015;10:e0142937
28. Markus MR, Meffert PJ, Baumeister SE,
et al. Association between hepatic steatosis
and serum liver enzyme levels with atrial ﬁbril-
lation in the general population: the Study of
Health in Pomerania (SHIP). Atherosclerosis
2016;245:123–131
29. Byrne CD, Targher G. Ectopic fat, insulin re-
sistance, and nonalcoholic fatty liver disease:
implications for cardiovascular disease. Arte-
rioscler Thromb Vasc Biol 2014;34:1155–1161
30. Del Ben M, Polimeni L, Carnevale R, et al.
NOX2-generated oxidative stress is associated
with severity of ultrasound liver steatosis in pa-
tients with non-alcoholic fatty liver disease.
BMC Gastroenterol 2014;14:81
31. Newton JL, Pairman J, Wilton K, Jones DE,
Day C. Fatigue and autonomic dysfunction in
non-alcoholic fatty liver disease. Clin Auton
Res 2009;19:319–326
32. Lee DH, Blomhoff R, Jacobs DR Jr. Is serum
gamma glutamyltransferase a marker of oxida-
tive stress? Free Radic Res 2004;38:535–539
33. Targher G, Byrne CD. Circulating markers of
liver function and cardiovascular disease risk.
Arterioscler Thromb Vasc Biol 2015;35:2290–
2296
34. Wang K, Li L, Wu Y, et al. Increased serum
gamma-glutamyltransferase levels are associ-
ated with ventricular instability in type 2 diabe-
tes. Endocrine 2016;52:63–72
35. Jeong EM, Liu M, Sturdy M, et al. Metabolic
stress, reactive oxygen species, and arrhythmia.
J Mol Cell Cardiol 2012;52:454–463
36. Yang KC, Kyle JW,Makielski JC, Dudley SC Jr.
Mechanisms of sudden cardiac death: oxidants
and metabolism. Circ Res 2015;116:1937–1955
37. Lee SS, Park SH. Radiologic evaluation of
nonalcoholic fatty liver disease. World J Gastro-
enterol 2014;20:7392–7402
38. Byrne CD, Targher G. Time to replace as-
sessment of liver histology with MR-based im-
aging tests to assess efﬁcacy of interventions for
nonalcoholic fatty liver disease. Gastroenterol-
ogy 2016;150:7–10
care.diabetesjournals.org Mantovani and Associates 1423
